Radiomic prediction for durable response to high‐dose methotrexate‐based chemotherapy in primary central nervous system lymphoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Haoyi Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Methotrexate, Central Nervous System Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital Health Research and Development of Special Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The rarity of primary central nervous system lymphoma (PCNSL) and treatment heterogeneity contributes to a lack of prognostic models for evaluating posttreatment remission. This study aimed to develop and validate radiomic‐based models to predict the durable response (DR) to high‐dose methotrexate (HD‐MTX)‐based chemotherapy in PCNSL patients.
Methods
A total of 159 patients pathologically diagnosed with PCNSL between 2011 and 2021 across two institutions were enrolled. According to the NCCN guidelines, the DR was defined as the remission lasting ≥1 year after receiving HD‐MTX‐based chemotherapy. For each patient, a total of 1218 radiomic features were extracted from prebiopsy T1 contrast‐enhanced MR images. Multiple machine‐learning algorithms were utilized for feature selection and classification to build a radiomic signature. The radiomic‐clinical integrated models were developed using the random forest method. Model performance was externally validated to verify its clinical utility.
Results
A total of 105 PCNSL patients were enrolled after excluding 54 cases with ineligibility. The training and validation cohorts comprised 76 and 29 individuals, respectively. Among them, 65 patients achieved DR. The radiomic signature, consisting of 8 selected features, demonstrated strong predictive performance, with area under the curves of 0.994 in training cohort and 0.913 in validation cohort. This signature was independently associated with the DR in both cohorts. Both the radiomic signature and integrated models significantly outperformed the clinical models in two cohorts. Decision curve analysis underscored the clinical utility of the established models.
Conclusions
This radiomic signature and integrated models have the potential to accurately predict the DR to HD‐MTX‐based chemotherapy in PCNSL patients, providing valuable therapeutic insights.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- National Genomics Data Center, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.
- CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
- Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.
ORCID-Profile: Xiaohui Ren
Förderung
- Capital Health Research and Development of Special Fund
Zitieren
APA
Li, H., Xiong, M., Li, M., Sun, C., Zheng, D., Yuan, L., Chen, Q., Lin, S., Liu, Z., & Ren, X. (2024). Radiomic prediction for durable response to high‐dose methotrexate‐based chemotherapy in primary central nervous system lymphoma. Cancer Medicine. https://doi.org/10.1002/cam4.70182
Vancouver
Li H, Xiong M, Li M, Sun C, Zheng D, Yuan L, et al. Radiomic prediction for durable response to high‐dose methotrexate‐based chemotherapy in primary central nervous system lymphoma. Cancer Medicine. 2024. doi:10.1002/cam4.70182
BibTeX
@article{Li2024,
author = {Li, Haoyi and Xiong, Mingming and Li, Ming and Sun, Caixia and Zheng, Dao and Yuan, Leilei and Chen, Qian and Lin, Song and Liu, Zhenyu and Ren, Xiaohui},
title = {Radiomic prediction for durable response to high‐dose methotrexate‐based chemotherapy in primary central nervous system lymphoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70182}
}
EUVIMED